Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Viridian Therapeutics, Inc.\De outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Viridian Therapeutics, Inc.\De is a mid-cap company with a market capitalization of $2.06B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for VRDN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VRDN included.
Follow VRDN free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | VRDN | Rank |
|---|---|---|
| Market Cap | $2.06B | 60/60 |
| P/B Ratio | 3.12x | 38/43 |
| Book Value/Share | $5.84 | – |
| Revenue/Share | $0.63 | – |
| FCF/Share | $-2.96 | – |
| Metric | VRDN | Rank |
|---|---|---|
| ROE | -58.5% | 25/33 |
| ROA | -35.3% | 32/39 |
| ROIC | -39.2% | 31/41 |
| Operating Margin | -570.8% | 30/33 |
| Net Margin | -545.1% | 30/33 |
| EBT Margin | -570.8% | 37/40 |
| Metric | VRDN | Rank |
|---|---|---|
| Current Ratio | 16.95x | 8/50 |
| D/E Ratio | 0.66x | 25/43 |
| Financial Leverage | 1.66x | 25/43 |
| Interest Coverage | -114.0x | 32/36 |
| Working Capital | $1.02B | 29/50 |
| Metric | VRDN | Rank |
|---|---|---|
| Operating Cash Flow | -$333M | 43/49 |
| Free Cash Flow | -$335M | 33/39 |
| Capital Spending | -$2M | 10/39 |
| FCF/Sales | -472.0% | 32/34 |
| CapEx/Sales | 2.4% | 19/34 |
| Metric | VRDN | Rank |
|---|---|---|
| Asset Turnover | 0.06x | 35/38 |
| Fixed Assets Turnover | 25.7x | 11/37 |
| Metric | VRDN | Rank |
|---|---|---|
| Total Revenue | $70M | 37/39 |
| Operating Income | -$405M | 35/41 |
| Net Income | -$386M | 33/40 |
| R&D Expense | $325M | 29/48 |
| Metric | VRDN | Rank |
|---|---|---|
| Shares Outstanding | 113M | – |
| Total Current Assets | $1.08B | 98.6% of assets |
| Cash & Short-term Investments | $165M | 15.0% of assets |
| Total Liabilities | $435M | 39.7% of assets |
| Short-term Debt | $55M | 5.0% of assets |
Companies classified under the same SEC industry code as Viridian Therapeutics, Inc.\De (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VRDN Viridian Therapeutics, Inc.\De | ▲ | $2.06B |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.73B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▲ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▼ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Viridian Therapeutics (VRDN) is a great medium term opportunity to bet on a well-differentiated next-generation therapy for Thyroid Eye Disease. Only competition is blockbuster Tepezza (Teprotumumab) ...
Viridian Therapeutics reported Q1 2026 EPS of -$0.90, beating estimates by $0.16 on May 5. Positive REVEAL-2 Phase 3 results for elegrobart in thyroid eye disease followed, alongside $350M capital ...
Viridian Therapeutics reported Q1 2026 earnings on May 5, beating EPS estimates by $0.16 at -$0.90 and surging revenue 95.8% YoY to $0.14M, exceeding forecasts. Viridian Therapeutics released its Q1 ...
Our AI ranks Viridian Therapeutics, Inc.\De outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for VRDN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Viridian Therapeutics, Inc.\De forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
60 issuers in our coverage, VRDN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.